Lei Yan

Synthesis and Activity of New Aryl- and Heteroaryl-Substituted Pyrazole Inhibitors of the Transforming Growth Factor-β Type I Receptor Kinase Domain

J. Scott Sawyer, Bryan D. Anderson, Douglas W. Beight et al. · Journal of Medicinal Chemistry · 2003 · 237 citations · Full text

Drug Target, Pyrazole-based Inhibitors, Pharmaceutical Chemistry +20

Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor

Jonathan M. Yingling, William T. McMillen, Lei Yan et al. · Oncotarget · 2017 · 168 citations · Full text

Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-β type I receptor kinase domain

J. Scott Sawyer, Douglas W. Beight, Karen S. Britt et al. · Bioorganic & Medicinal Chemistry Letters · 2004 · 161 citations

Molecular Pharmacology, Medicinal Chemistry, Pharmaceutical Chemistry +9

LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models

S. Betty Yan, Victoria L. Peek, Rose T. Ajamie et al. · Investigational New Drugs · 2012 · 159 citations · Full text

Reduced SMAD7 Leads to Overactivation of TGF-β Signaling in MDS that Can Be Reversed by a Specific Inhibitor of TGF-β Receptor I Kinase

Li Zhou, Christine M. McMahon, Tushar D. Bhagat et al. · Cancer Research · 2010 · 132 citations · Full text

Smad7 Leads, Tgf-β Receptor, Immunology +23